Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV™ (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19

Corporate Breaking News

Home : Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV™ (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19

Apr 12 2021	Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV™ (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19
TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/ -- Second Phase 3 trial undertaken in collaboration with NIAID to announce results today, both using subcutaneous administration of REGEN-COV in asymptomatic individuals without prior COVID-19 infection Regeneron Pharmaceuticals, Inc. (NASDAQ:...


Source:https://www.prnewswire.com:443/news-releases/phase-3-treatment-trial-in-recently-infected-asymptomatic-patients-showed-regen-cov-casirivimab-with-imdevimab-significantly-reduced-progression-to-symptomatic-covid-19-301266398.html

Related News
» Hand Sanitizer Market in India Analysis and Forecast Report 2021-2025 with Q1,2021 COVID-19 Impact Update\|Technavio » Cosmo announces FDA approval of GI Genius™ intelligent endoscopy module, its revolutionary Artificial Intelligence device for lesion detection during colonoscopy